|
Post by RLC on Jul 23, 2015 12:12:42 GMT
ir.oncosec.com/press-releases/detail/1834/oncosec-to-webcast-annual-meeting-of-stockholdersSAN DIEGO, July 23, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, invites investors and the general public to its Annual Shareholder Meeting at 9:00 AM PT/12:00 PM ET on Friday, July 31, 2015. The meeting will be held at the following location: 10996 Torreyana Road, Lighthouse Room, San Diego, California 92121. A live webcast of the meeting will also be available. Please use the following link to register for the meeting: engage.vevent.com/rt/oncosecmedicalincorporated~073115. An archived version of the webcast will be available for 90 days on OncoSec's website: www.oncosec.com. To access the Notice of Annual Meeting of Stockholders and Proxy Statement, which describe the formal business to be conducted at the meeting, please click here.
|
|
|
Post by RLC on Jul 23, 2015 12:31:18 GMT
Here are the proxy items:
To the Stockholders of OncoSec Medical Incorporated:
The 2015 Annual Meeting of Stockholders (the "Annual Meeting") of OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") will be held on July 31, 2015 at 9:00 a.m., Pacific Time, in the Lighthouse room located at 10996 Torreyana Road, San Diego, California 92121, for the following purposes, which are further described in the accompanying proxy statement (the "Proxy Statement"):
(1) to elect four directors to our Board of Directors to serve for a term of one year or until their successors are duly elected and qualified;
(2) to ratify the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ending July 31, 2015;
(3) to amend the 2011 Stock Incentive Plan to increase the shares reserved for issuance thereunder and increase the annual per person limit on stock options, stock appreciation rights, restricted stock and restricted stock units that are intended to qualify for exclusion from the federal tax deduction limitation under Section 162(m) of the Internal Revenue Code; and
(4) to transact other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
|
|
Post by RLC on Jul 23, 2015 12:32:25 GMT
PROPOSAL 3
AMENDMENT AND RESTATEMENT OF THE 2011 STOCK INCENTIVE PLAN
The Board has approved, subject to and contingent on shareholder approval, an amendment and restatement of the OncoSec Medical Incorporated 2011 Stock Incentive Plan (the "2011 Plan") to increase the number of shares of common stock authorized for issuance thereunder by 1,879,722 shares to 3,500,000 shares and to increase the annual per person limit on stock options, stock appreciation rights, restricted stock and restricted stock units that are intended to qualify for exclusion from the federal tax deduction limitation under Section 162(m) of the Internal Revenue Code.
The Board adopted the 2011 Plan for directors, employees and consultants on August 5, 2011. The 2011 Plan was approved by our stockholders in March 2012 and originally authorized the Board of Directors to grant equity awards to employees, directors, and consultants for up to 5,200,000 shares of our common stock. On April 15, 2013, our stockholders approved an amendment to the 2011 Plan to authorize the issuance of an additional 3,800,000 shares of our common stock under the 2011 Plan and on July 18, 2014 our stockholders approved an amendment to the 2011 Plan to authorize the issuance of an additional 16,000,000 shares of our common stock under the 2011 Plan, increasing the total number of shares reserved for issuance under the 2011 Plan to 25,000,000 shares.
Following the reverse stock split approved by our Board and effective as of May 18, 2015, each 20 shares of issued and outstanding common stock and warrants, respectively, were combined into and became one share of common stock, and no fractional shares were issued. The number of authorized shares of common stock was reduced proportionately to the number of outstanding shares of common stock reduced. Accordingly, the total number of shares of common stock reserved for issuance under the 2011 Plan was reduced following the reverse stock split to 1,620,278 shares, and the annual per-individual grant limitation was reduced to 100,000 shares.
An increase of 1,879,722 shares of common stock would bring the total reserve under the 2011 Plan from 1,620,278 shares reserved to 3,500,000 shares. Of the shares previously approved, 889,244 shares of common stock remain available for grant as of June 10, 2015. If approved, and in conjunction with the proposed increase to the annual per-individual grant limitation under the 2011 Plan to 500,000 shares, we expect to use the additional authorized shares to attract, motivate and retain high-performing individuals as employees (including executive officers), directors and consultants. Other than this, we currently have no plans, proposals or arrangements, written or otherwise, to issue any of the additional authorized shares of common stock.
The following table provides information about our outstanding stock options as of June 10, 2015, on a post-split basis. Approximately 65% of outstanding stock options were exercisable on that date and 52% of exercisable options had exercise prices above the closing price on that date. There have been no grants of stock appreciation rights, restricted stock, or restricted stock units under the 2011 Plan. There have been two grants of Restricted Stock Bonuses to consultants under the 2011 Plan. Each Restricted Stock Bonus grant was for 75,000 shares and was made on December 8, 2014.
.....
|
|
|
Post by RLC on Jul 23, 2015 12:38:29 GMT
After OCAT's proxy, this 2x increase in incentive shares seems generous . Still can't believe OCAT received approval to increase incentive shares by 15x!
|
|
|
Post by JHam on Jul 23, 2015 15:23:44 GMT
ir.oncosec.com/press-releases/detail/1834/oncosec-to-webcast-annual-meeting-of-stockholdersSAN DIEGO, July 23, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, invites investors and the general public to its Annual Shareholder Meeting at 9:00 AM PT/12:00 PM ET on Friday, July 31, 2015. The meeting will be held at the following location: 10996 Torreyana Road, Lighthouse Room, San Diego, California 92121. A live webcast of the meeting will also be available. Please use the following link to register for the meeting: engage.vevent.com/rt/oncosecmedicalincorporated~073115. An archived version of the webcast will be available for 90 days on OncoSec's website: www.oncosec.com. To access the Notice of Annual Meeting of Stockholders and Proxy Statement, which describe the formal business to be conducted at the meeting, please click here. I'll definitely be tuning into this. I don't think they have ever webcast an ASM meeting before, so there should be good reason for them to do so, i.e. first patient in P2b enrolled, MCC data, etc...
|
|
|
Post by furbush87 on Jul 23, 2015 16:02:05 GMT
ir.oncosec.com/press-releases/detail/1834/oncosec-to-webcast-annual-meeting-of-stockholdersSAN DIEGO, July 23, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, invites investors and the general public to its Annual Shareholder Meeting at 9:00 AM PT/12:00 PM ET on Friday, July 31, 2015. The meeting will be held at the following location: 10996 Torreyana Road, Lighthouse Room, San Diego, California 92121. A live webcast of the meeting will also be available. Please use the following link to register for the meeting: engage.vevent.com/rt/oncosecmedicalincorporated~073115. An archived version of the webcast will be available for 90 days on OncoSec's website: www.oncosec.com. To access the Notice of Annual Meeting of Stockholders and Proxy Statement, which describe the formal business to be conducted at the meeting, please click here. I'll definitely be tuning into this. I don't think they have ever webcast an ASM meeting before, so there should be good reason for them to do so, i.e. first patient in P2b enrolled, MCC data, etc... I think it has more to do with a growing desire to engage their investors. I could be wrong
|
|
|
Post by jckrdu on Jul 27, 2015 17:14:25 GMT
Today's retest back to $6 is on fairly light volume. Just an observation fwiw.
|
|
|
Post by JHam on Jul 31, 2015 13:27:39 GMT
Presumably they are going to release Q2 earnings before the call right?
|
|
|
Post by jckrdu on Jul 31, 2015 14:30:35 GMT
Presumably they are going to release Q2 earnings before the call right? Maybe not because this is the annual shareholders meeting.
|
|
|
Post by JHam on Jul 31, 2015 16:10:01 GMT
Presumably they are going to release Q2 earnings before the call right? Maybe not because this is the annual shareholders meeting. You were correct. Listening to the call now. All proposals passed. PD on the call now.
|
|
|
Post by JHam on Jul 31, 2015 16:14:09 GMT
Happy to announce that P2b is currently open and screening patients.
|
|
|
Post by JHam on Jul 31, 2015 16:15:27 GMT
Merkel Cell data will presented at ASMO and could provide more proof that IL-12 works.
|
|
|
Post by JHam on Jul 31, 2015 16:38:15 GMT
Aaaand it's over. Nothing really new, but it was nice to listen to Dr. Pierce go into detail about a few aspects of the science especially regarding the Heat collaboration. At one point PD was asked by a shareholder in the audience about value creation this year, potentially due to data readouts. Dr. Pierce chimed in and reminded the guy that the MCC data at ASMO would happen this year.
My thoughts were basically confirmed. We are likely going to just sit and wait until data readouts.
|
|
|
Post by RLC on Jul 31, 2015 16:44:54 GMT
Aaaand it's over. Nothing really new, but it was nice to listen to Dr. Pierce go into detail about a few aspects of the science especially regarding the Heat collaboration. At one point PD was asked by a shareholder in the audience about value creation this year, potentially due to data readouts. Dr. Pierce chimed in and reminded the guy that the MCC data at ASMO would happen this year. My thoughts were basically confirmed. We are likely going to just sit and wait until data readouts. And I just knew we were going to hear about the buyout offer from Merck Hopefully we don't see too much PPS deterioration while we wait....
|
|
|
Post by JHam on Jul 31, 2015 16:46:17 GMT
Aaaand it's over. Nothing really new, but it was nice to listen to Dr. Pierce go into detail about a few aspects of the science especially regarding the Heat collaboration. At one point PD was asked by a shareholder in the audience about value creation this year, potentially due to data readouts. Dr. Pierce chimed in and reminded the guy that the MCC data at ASMO would happen this year. My thoughts were basically confirmed. We are likely going to just sit and wait until data readouts. And I just knew we were going to hear about the buyout offer from Merck Hopefully we don't see too much PPS deterioration while we wait.... Here is my quick recap from notes that i jotted down in my brain: MCC data will be presented at ESMO. In fact, when PD was asked by a shareholder in the audience about value creating events, Dr. Pierce chimed in to re-iterate that MCC data would be presented at ESMO. I'll let you draw your own conclusions. Pierce also gave some very cool details on the Heat Bio collaboration. Another big point was Pierce explaining that if the data is spectacular, things could move along much faster, as the FDA has track record of doing so. He also mentioned in the same response that there are several companies with comparable anti-PD-1 drugs. If ONCS can prove that they can do what they say, they will look forward to the conversations with all of those companies.
|
|
|
Post by furbush87 on Jul 31, 2015 17:08:16 GMT
And I just knew we were going to hear about the buyout offer from Merck Hopefully we don't see too much PPS deterioration while we wait.... Here is my quick recap from notes that i jotted down in my brain: MCC data will be presented at ESMO. In fact, when PD was asked by a shareholder in the audience about value creating events, Dr. Pierce chimed in to re-iterate that MCC data would be presented at ESMO. I'll let you draw your own conclusions. Pierce also gave some very cool details on the Heat Bio collaboration. Another big point was Pierce explaining that if the data is spectacular, things could move along much faster, as the FDA has track record of doing so. He also mentioned in the same response that there are several companies with comparable anti-PD-1 drugs. If ONCS can prove that they can do what they say, they will look forward to the conversations with all of those companies. I think the Q&A was very telling. Basically said that the collaborations with Heat and Plexxikon both are doing very well, so most likely will end in partnerships, in addition the description of how Heat's drug actually works and how IL-12 will interact with it makes me think that may prove to be a game winning investment opportunity as well.
|
|
|
Post by jckrdu on Aug 1, 2015 0:28:38 GMT
And I just knew we were going to hear about the buyout offer from Merck Hopefully we don't see too much PPS deterioration while we wait.... Here is my quick recap from notes that i jotted down in my brain: MCC data will be presented at ESMO. In fact, when PD was asked by a shareholder in the audience about value creating events, Dr. Pierce chimed in to re-iterate that MCC data would be presented at ESMO. I'll let you draw your own conclusions. Pierce also gave some very cool details on the Heat Bio collaboration. Another big point was Pierce explaining that if the data is spectacular, things could move along much faster, as the FDA has track record of doing so. He also mentioned in the same response that there are several companies with comparable anti-PD-1 drugs. If ONCS can prove that they can do what they say, they will look forward to the conversations with all of those companies. Looks like final Merkel data is being presented on Sunday, Sept 27th at the European Cancer Congress.
I certainly like the title of the presentation:
"Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 study"
Speaker: S. Bhatia (USA)
www.europeancancercongress.org/Scientific-Programme/Searchable-Programme#anchorScpr
|
|
|
Post by jckrdu on Aug 1, 2015 0:47:39 GMT
Here is my quick recap from notes that i jotted down in my brain: MCC data will be presented at ESMO. In fact, when PD was asked by a shareholder in the audience about value creating events, Dr. Pierce chimed in to re-iterate that MCC data would be presented at ESMO. I'll let you draw your own conclusions. Pierce also gave some very cool details on the Heat Bio collaboration. Another big point was Pierce explaining that if the data is spectacular, things could move along much faster, as the FDA has track record of doing so. He also mentioned in the same response that there are several companies with comparable anti-PD-1 drugs. If ONCS can prove that they can do what they say, they will look forward to the conversations with all of those companies. Looks like final Merkel data is being presented on Sunday, Sept 27th at the European Cancer Congress.
I certainly like the title of the presentation:
"Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 study"
Speaker: S. Bhatia (USA)
www.europeancancercongress.org/Scientific-Programme/Searchable-Programme#anchorScpr
I also thought we identified an earlier conference on 9/9 where Merkel data was going to be presented. Anyone recall that?
|
|
|
Post by furbush87 on Aug 2, 2015 15:55:22 GMT
Looks like final Merkel data is being presented on Sunday, Sept 27th at the European Cancer Congress.
I certainly like the title of the presentation:
"Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 study"
Speaker: S. Bhatia (USA)
www.europeancancercongress.org/Scientific-Programme/Searchable-Programme#anchorScpr
I also thought we identified an earlier conference on 9/9 where Merkel data was going to be presented. Anyone recall that? "Thanks furbush for noticing the change in date. Adil Daud will present on September 9, at the 1st. WCE a lecture titled clinical trials with plasmid IL-12 electroporation in melanoma and Merkel cell cancer." Guti on yahoo. Though I don't know what WCE stands for, and never verified this.
|
|
|
Post by investordoc on Aug 2, 2015 17:18:13 GMT
|
|